Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Tourism Northern Ireland has described the recent Amgen Irish Open in Co Down as “incredibly successful”. More than 71,000 ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

In addition to Dr. Bachleda, members of the Eyconis Board of Directors include Dr. Cunningham, who serves as Executive Chair, Jan Mikkelsen, President & CEO of Ascendis Pharma A/S, Daniel Estes, Ph.D.

ALS, MS, post-traumatic brain injury? This biotech company has a target choice to make for an upcoming clinical trial — and ...

The Congressional Black Caucus Foundation's Annual Legislative Conference panel on the Road to Health Equity discussed the ...

On June 28, 2024, the United States Patent and Trademark Office (“USPTO”) requested the public’s views on the current state ...